ENDRA Life Sciences Files Additional Proxy Materials
Ticker: NDRA · Form: DEFA14A · Filed: Sep 17, 2024 · CIK: 1681682
| Field | Detail |
|---|---|
| Company | Endra Life Sciences INC. (NDRA) |
| Form Type | DEFA14A |
| Filed Date | Sep 17, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, sec-filing, corporate-governance
TL;DR
ENDRA Life Sciences dropped more proxy docs, no fee needed.
AI Summary
ENDRA Life Sciences Inc. filed a Definitive Additional Materials (DEFA14A) on September 17, 2024, related to its proxy statement. The filing concerns the company's operations and shareholder matters, with no fee required for this submission.
Why It Matters
This filing provides updated or supplementary information to shareholders regarding ENDRA Life Sciences' corporate governance and voting matters, which is crucial for informed decision-making by investors.
Risk Assessment
Risk Level: low — This filing is a routine administrative submission for proxy materials and does not contain new financial information or strategic changes that would inherently increase risk.
Key Players & Entities
- ENDRA Life Sciences Inc. (company) — Registrant
- 0001654954-24-011977 (filing_id) — Accession Number
- 20240917 (date) — Filing Date
FAQ
What type of SEC filing is this?
This is a DEFA14A filing, specifically 'Definitive Additional Materials' related to a proxy statement.
Who is the registrant for this filing?
The registrant is ENDRA Life Sciences Inc.
When was this filing submitted?
The filing was submitted on September 17, 2024.
Was there a fee required for this filing?
No, the filing indicates that no fee was required.
What is the purpose of a DEFA14A filing?
A DEFA14A filing is used to submit definitive additional materials that are supplemental to a proxy statement previously filed with the SEC.
Filing Stats: 142 words · 1 min read · ~1 pages · Grade level 12 · Accepted 2024-09-16 17:53:09
Filing Documents
- shn_defa14a.htm (DEFA14A) — 9KB
- shn_defa14aimg2.jpg (GRAPHIC) — 151KB
- shn_defa14aimg3.jpg (GRAPHIC) — 101KB
- 0001654954-24-011977.txt ( ) — 357KB
From the Filing
14A shn_defa14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to Rule 14a-12 ENDRA LIFE SCIENCES INC. (Name of Registrant as Specified in its Charter) ___________________________________________________ (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee previously paid with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. 2 3